BUZZ-Ocular Therapeutix hires veteran to lead commercial push for eye drugs; shares up

Reuters01-21
BUZZ-<a href="https://laohu8.com/S/OCUL">Ocular Therapeutix</a> hires veteran to lead commercial push for eye drugs; shares up

** Shares of biopharma firm Ocular Therapeutix OCUL.O rise 2.67% to $11.76 premarket

** Company says it has hired industry veteran David Robinson as global chief commercial officer to steer plans for experimental eye drug axpaxli for wet age‑related macular degeneration and diabetic eye disease

** Axpaxli is an experimental treatment in late‑stage trials; the diseases cause vision loss due to damage in retinal blood vessels - company

** OCUL says Robinson previously helped launch blockbuster retina drug Eylea and most recently led global ophthalmology marketing at Merck MRK.N

** He oversees commercial strategy and works alongside Steve Meyers, who remains CCO for approved eye‑surgery treatment Dextenza - OCUL

** Shares up ~42% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment